CORT Corcept Therapeutics Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NASDAQ: CORT
  4. Earnings
?
Relative Growth: Rel. Growth: 44
Relative Strength: Rel. Strength: 92
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 43

EPS in 2026 (TTM): $0.46

Last Report Period Date: Mar 31, 2026

As of July 2026, according to Corcept Therapeutics's current financial statements, the company's 12-month EPS is $0.46. Corcept Therapeutics's EPS for 2025 amounted to $0.95, marking a drop from $1.35 in 2024. Corcept Therapeutics's earnings per share for the quarterly report ending on Mar 31, 2026 reached -$0.3.

CORT earnings history

Historical annual and quarterly earnings per share (EPS) data for Corcept Therapeutics
EPS (TTM)
$0.46
EPS Growth YoY (Quarterly)
-257.9%
EPS (Quarterly)
-$0.3
EPS Growth (Quarterly)
-225%

The annual EPS for the year 2025 was $0.95, a drop of 29.6% from $1.35 in 2024. The quarterly per-share earnings for the period ending Mar 31, 2026, was -$0.3, indicating a 257.9% decrease from the same quarter last year. CORT's 12-month EPS stands at $0.46 as of March 2026. Corcept Therapeutics's annual EPS in 2024 stood at $1.35, a 32.4% increase year-over-year.

CORT earnings chart

CORT EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
-257.9%
EPS growth YoY
-29.6%
EPS growth 3Y avg
0%
EPS growth 5Y avg
0.6%

During the last 12 months, Corcept Therapeutics has seen an EPS growth of -257.9% (YoY, quarterly). Throughout the last three years, the company had an average EPS growth of 0% per year. During the last 5 years, the company had an average EPS growth rate of 0.6%.

CORT Earnings Waterfall

Breakdown of revenue, profit and net income for Corcept Therapeutics

CORT Earnings vs Peers

What are the earnings of CORT compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
BMY Bristol Myers Squibb Co 16.28 178.7% 5.3% N/A
PFE Pfizer Inc 18.56 -3.5% -37.4% -3.7%
NVS Novartis AG 22.78 21.8% 31.2% 15.2%
JNJ Johnson & Johnson 30.13 90.6% 17.7% 14.8%
MRK Merck & Co Inc 36.29 8% 8.4% 21.2%
BMRN Biomarin Pharmaceutical Inc 42.14 -19.1% 33.8% -17.4%
LLY ELI LILLY & Co 43.06 95.6% 49.2% 27.5%
CORT Corcept Therapeutics Inc 196.11 -29.6% 0% 0.6%
ESPR Esperion Therapeutics Inc N/A 60.7% N/A N/A
MNKD Mannkind Corp N/A -80% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.